Mary E. Laker
Royal Veterinary College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mary E. Laker.
Biochimica et Biophysica Acta | 1984
Mary E. Laker; Peter A. Mayes
In the rat liver perfused with whole rat blood containing either decreased or increased concentrations of non-esterified fatty acids, insulin decreased production of acetoacetate and 3-hydroxybutyrate and stimulated secretion of very-low-density-lipoprotein triacylglycerol. In these same livers, pyruvate dehydrogenase activity was not altered by insulin addition, although it was diminished by non-esterified fatty acids.
Biochemical Pharmacology | 1979
Mary E. Laker; Peter A. Mayes
Abstract A study was made of the immediate effects of CPIB (chlorophenoxy-isobutyrate) and of the effects of clofibrate (ethyl-CPIB) pretreatment on the metabolism of the perfused liver. Both treatments caused an increased hepatic uptake of lactate and free fatty acids. Pretreatment with clofibrate resulted in a decrease in perfusate glucose, an increase in ketogenesis and a decreased output of very low density lipoprotein triacylglycerol. A more oxidized redox state of both the cytosol and the mitochondria was indicated by decreased ratios of perfusate [lactate]/[pyruvate] and [3-hydroxybutyrate]/[acetoacetate] respectively. Increased hepatic O 2 consumption was associated with the increased liver weight of rats treated with the drug for 1 week. The fate of free fatty acids was followed by infusing [1— 14 Cloleate. The increased oxidation of oleate to both CO 2 and ketone bodies in livers from animals pretreated with clofibrate was accompanied by a corresponding decreased incorporation of 14 C into very low density lipoprotein triacylglycerol. Lipogenesis was depressed upon addition of CPIB to the perfusate, but was increased after pretreatment with clofibrate. No changes in cholesterol synthesis were detected. A hypothesis to account for the hypolipidaemic and other effects of clofibrate pretreatment is advanced. This is based on a primary enhancement of fatty acid oxidation accompanied by a reciprocal decrease in hepatic triacylglycerol secretion. It is suggested that increased peroxisomal oxidation of fatty acids may be a cause of the decreased redox potential. A consequent activation of pyruvate dehydrogenase would explain both the changes in carbohydrate metabolism and the increase in lipogenesis.
Biochemical Journal | 1981
Mary E. Laker; Peter A. Mayes
Biochemical Society Transactions | 1981
Peter A. Mayes; Mary E. Laker
Biochemical Society Transactions | 1976
Mary E. Laker; Peter A. Mayes
Biochemical Society Transactions | 1978
Mary E. Laker; Peter A. Mayes
Biochemical Society Transactions | 1985
Mary E. Laker; Peter A. Mayes
Biochemical Society Transactions | 1979
Mary E. Laker; Peter A. Mayes
Biochemical Society Transactions | 1982
Mary E. Laker; Peter A. Mayes
Biochemical Society Transactions | 1981
Mary E. Laker; Peter A. Mayes